Observed Neutralizing Antibody Response by Age Groups.
SARS-COV-2 INFECTION
Observed neutralizing antibody titers (GM titer log10) in the pseudovirus assay against Omicron BA.4/BA.5 (a) and ancestral SARS-CoV-2 (D614G) (b) are shown for serum samples collected before the second booster dose of 50-µg of mRNA-1273.222 or 50-µg of mRNA-1273 (prebooster) (day 0), and at 28 days (day 29) after the second booster dose in all participants and those ≥18 to <65 or ≥65 years of age in the per-protocol immunogenicity set without evidence of prebooster SARS-CoV-2 infection. N=Number of participants with nonmissing data at the timepoint; CI=Confidence interval; GMT=geometric mean titer; LLOQ=lower limit of quantification; ULOQ=upper limit of quantification; PPIS=Per-protocol immunogenicity set. Antibody values assessed by pseudovirus neutralizing antibody assay reported as below the LLOQ (18.5 [1.3 in log10 scale] for ancestral SARS-CoV-2 (D614G) and 36.7 [1.6 in log10 scale] for Omicron BA.4/BA.5) are replaced by 0.5 × LLOQ. Values greater than ULOQ (45,118 [4.7 in log10 scale] for ancestral SARS-CoV-2 (D614G) and 13,705 [4.1 in log10 scale] for Omicron BA.4/BA.5) are replaced by the ULOQ if actual values are not available. Includes participants in the per-protocol immunogenicity set without evidence of prebooster SARS-CoV-2 infection (PPIS-negative). 95% CIs were calculated based on the t-distribution of the log-transformed values for GM value, then back-transformed to the original scale for presentation.
